Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
25/09/2026 22:46
BRIEF-NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments Sept 26 (Reuters) - NervGen Pharma Corp NGEN.O:
NERVGEN TO RESTATE PREVIOUSLY FILED FINANCIAL STATEMENTS RECOGNIZING NON-CASH ACCOUNTING ADJUSTMENTS
NERVGEN - TO RESTATE FY2025 AUDITED AND Q2 2026 UNAUDITED FINANCIAL STATEMENTS
NERVGEN - RESTATEMENT EXPECTED TO REDUCE STOCK-BASED COMPENSATION EXPENSE, WARRANT LIABILITIES, AND ACCUMULATED DEFICIT
NERVGEN - RESTATEMENT REVISES VALUATION OF WARRANTS AND OPTIONS, REDUCES STOCK-BASED COMPENSATION EXPENSE
NERVGEN - ADJUSTMENTS HAVE NO IMPACT ON CASH, CASH RUNWAY, OR BUSINESS OPERATIONS
NERVGEN - REMAINS ON TRACK TO REPORT Q3 2026 FINANCIAL RESULTS
Source text: ID:nGNXbSh81x
Further company coverage: NGEN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nervgen Pharma
See all newsBrief: Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury
Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Brief: Nervgen Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive